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An estimated 22,000 Danes live with diabetic foot ul-
cers (DFU), and the annual incidence is around 3,000 
[1]. The condition is associated with shorter survival 
and an increased risk of amputation of the affected 
limb [2, 3]. Currently, 4,000 people in Denmark are 
living with amputation due to non-healing DFUs [1]. 
Mortality is increased three-fold in persons with DFUs 
compared with diabetics who have no DFUs [3]. A re-
cent Danish study showed a mean survival of 2.5 years 
after the first amputation, with a five-year mortality 
rate of 43% and 52%, among patients with Type 1 and 
Type 2 diabetes, respectively [4]. In fact, DFU was re-
cently shown to be independently associated with an 
increased risk of death, both with and without other co-
morbidity risk factors [3, 5-8]. 
DFUs and lower-extremity amputations are major 
medical and financial challenges for the affected indi-
vidual and for society [9]. The pathogenesis of DFU is a 
triopathy related to neuropathy, microangiopathy and 
an altered response to infection. The result is functional 
ischaemia due to inability of the vascular bed to in-
crease the blood flow in response to stress [10]. In re-
cent years, randomised, placebo-controlled studies 
(RCT) have found that hyperbaric oxygen therapy 
(HBOT) accelerates wound healing in persons with 
DFUs. International guidelines, based on a small num-
ber of RCTs and observational studies, recommend 
HBOT as an adjuvant therapy for DFUs [11-14]. HBOT 
is currently a treatment modality with limited capacity. 
It is of high priority to ensure that HBOT is offered to a 
patient population suitable for intervention regarding 
effect, compliance and life expectancy.  
This study aimed to describe the population of DFU 
patients who were treated with HBOT in Denmark du-
ring the 1999-2015 period. This includes referral pat-
tern, comorbidity, adherence to the standard HBOT re-
gimen, and prognosis described as survival and time to 
first amputation after HBOT.
METHODS
Data source and linkage 
The patient cohort was identified using the HBOT data-
base, which is an electronic registry of all patients tre-
ated at the HBO chamber at Rigshospitalet, Copenha-
gen, from January 1996 through 2016. Registered data 
include Civil Registration Number (CRN), referral diag-
nosis, referral source and technical treatment details. 
Electronic patient records were available for pa-
tients referred after 2005. 
ABSTRACT
INTRODUCTION: Patients with diabetic foot ulcers (DFU) 
suffer from diabetes-related complications and comor-
bidities. Hyperbaric oxygen therapy (HBOT) is a treatment 
modality with limited capacity used in the treatment of 
DFUs. It is important to ensure that HBOT is offered to 
patients who are suitable for this treatment regarding effect, 
compliance and life expectancy. The objective of the present 
study was to describe the population of patients with DFU 
who were referred to HBOT in Denmark in the 1999-2016 
period. 
METHODS: All patients with DFU who were treated at the 
HBOT chamber in Copenhagen during the study period were 
considered. Patients with an invalid social security number 
or an incorrect diagnosis were excluded. Data on comor-
bidities, amputation and death were extracted from the 
Danish National patient Registry and the Danish Civil 
Registration System. Continuous data were described as 
median values and binary data were described as 
proportions. The probability estimate for survival and 
amputation was investigated by constructing Kaplan-Meier 
curves. 
RESULTS: The cohort included 148 patients. Patients were 
mainly referred from the Capital Region (92%) and multi-
disciplinary wound care centres were the primary referring 
departments (67%). Comorbidity rates were high with an 
initial median Charlson Comorbidity Index score of five. The 
five-year amputation and mortality estimates after referral 
were 73.5% and 51.8%, respectively. 
CONCLUSIONS: The study showed that Danish DFU patients 
who are offered HBOT are in advanced stages of their 
disease, and the referral hinges on local factors such as 
geography and the referring source rather than on 
standardised procedures.
FUNDING: none.
TRIAL REGISTRATION: not relevant.
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The Danish National Patient Registry (DNPR) con-
tains information on persons who have been admitted 
to somatic hospital departments since 1977. As of 
1995, ambulatory and emergency department patients 
are also included in the register. Each hospital dis-
charge or outpatient visit is recorded with one primary 
diagnosis and up to twenty secondary diagnoses, clas-
sified according to the International Classification of 
Diseases, tenth edition (ICD-10) since the end of 1993, 
and according to the ICD-8 before then. The DNPR also 
contains codes for surgery and procedures according to 
the Surgery and Treatment Classification from 1977 
until 1999, and according to the ICD-10 thereafter.
The Danish Civil Registration System (CRS) was 
established in 1968, and all persons who are alive and 
living in Denmark since 1968 are registered with their 
CRN. Among many other variables, the CRS includes 
continuously updated information on vital status. Data 
were linked at individual level through the CRN.
Study population
All patients treated for DFUs in the HBO chamber at 
Rigshospitalet, Copenhagen, from January 1999 
through December 2015, were identified via the HBOT 
database. Patients referred before 2005 were excluded 
if they had no diabetes diagnosis registered in the 
DNPR. Patients referred after 2005 were excluded if a 
DFU was not described in their electronic patient re-
cord up to the time of referral.
Variables and definitions
Data on referring source, hospital and region as well as 
number of referrals and completed HBOT sessions 
were obtained from the HBOT database. Using the 
DNPR, we extracted diagnoses coupled to comorbid-
ities and lower-extremity amputations up to the time of 
the first HBOT session. Data on survival were obtained 
through the CRS. Minor amputations were defined as 
below and through the ankle, and major amputations 
were above the ankle. The Charlson Comorbidity Index 
(CCI) was calculated based on discharge diagnostic co-
des found in the DNPR from 1977 until the time of re-
ferral [15]. The standard HBOT was defined as a mini-
mum of 30 sessions of 90 minutes of continuous 
oxygen breathing to a pressure of 2.4-2.5 atm abs. 
Data analysis
Continuous variables were described as median values 
with range and inter-quartile range, and binary vari-
ables were described as proportions. Percentages are 
calculated from a total where unknown has been ex-
cluded. We measured the time from first HBOT to de-
ath and to first amputation, both for patients who had 
previous amputations and patients who had not under-
gone any amputations prior to their referral to HBOT, 
and constructed Kaplan-Meier survival curves. Statis-
tical analyses were performed with STATA, version 
13.1. 
Approval
The study was approved by the Danish Health and  
Medicines Authority and the Danish Data Protection 
Agency. The study was exempted from approval from 
the Regional Ethics Committee as no intervention was 
involved [16]. 
Trial registration: not relevant.
RESULTS
A total of 213 patients with DFU were extracted from 
the HBOT database. Sixty-five patients were excluded, 
five of whom were foreign citizens with a temporary 
CRN, three had invalid CRNs and one patient was re-
gistered twice in the database. Of the remaining 204 
patients, 150 patients had electronic patient records. 
TABLE 1
Demographics and risk 
factors variables at the 
time of referral: demo­
graphics, Charlson  
Comorbidity Index and 
the number of patients 
who were diagnosed 
with specific diagnosis 
coupled to diabetes 
and other comorbidities 
according to The Dan­
ish National Patient  
Registry. 
N = 148; median age  
= 66 (range: 34­94)  
years.
n (%)
General characteristics 
Male 120 (82)
Female   28 (19)
Diabetes and diabetes specific complications
Diabetes, Type 1   99a (67)
Diabetes, Type 2 127a (86)
Unspecified diabetes 107a (72)
Retinopathy   56 (38)
Peripheral neuropathy     9 (6)
Nephropathy   11 (7.4)
Comorbidity
Hypertension   84 (57)
Dyslipidaemia   49 (33)
Dementia     1 (0.7)
Myocardial infarction   28 (19)
Congestive heart failure   37 (25)
Cerebrovascular disease   41 (28)
Peripheral vascular disease 126 (85)
Diabetes with end-organ-damage 125 (85)
Chronic pulmonary disease   22 (15)
Severe liver disease     1 (0.7)
Kidney disease: moderate-severe   33 (22)
Malignancy   19 (13)
Peptic ulcer disease   12 (8)
Connective tissue disease   10 (7)
AIDS     1 (0.7)
Foot-specified comorbidity
≥ 1 lower extremity amputation   71 (48)
Charcot foot   10 (7)
a)  Patients receiving the diagnosis as extracted from the Danish National 
Patient Registry, illustrating imprecisely registered diabetes subtypes in 
the Danish National Patient Registry.
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Of those, 44 patients were excluded because their DFU 
diagnosis could not be confirmed in their records. Fin-
ally, we excluded 12 of the 54 patients with a paper re-
cord only who had never been diagnosed with diabetes 
according to the DNPR. The final cohort included n = 
148 patients with DFU who had been treated in the 
HBO chamber during the 1999-2015 period.
Characteristics of referred patients
Demographics and risk variables at the time of referral 
are presented in Table 1. The median patient age was 
66 years (range: 34-94 years) with 82% men, and the 
majority had diabetes end-organ damage (85%). The 
most common comorbid conditions were cerebrovas-
cular disease (28%), congestive heart failure (25%), 
chronic kidney disease (22%) and myocardial infarc-
tion (19%). Figure 1 shows the distribution of CCI  
scores for the entire cohort with a mean of 5.2 (stan-
dard deviation (SD): ± 2.2). A large proportion (79%) 
of patients had CCI scores > 3, and 44% of referred pa-
tients had a CCI score ≥ 6. In the investigated cohort, 
71 (47%) patients had undergone amputations at the 
time of referral; and among them, a total of 277 ampu-
tating procedures were made; 130 minor and 147  
major. Ten patients were diagnosed with the limb-
threat en ing inflammatory diabetic complication of 
Charcot foot. 
Referral pattern
The number of patients referred for HBOT of a DFU in-
creased abruptly in 2010 with a mean of 5.4 per year 
patients during the period of 1999-2009 and 15.5 pa-
tients per year between 2010 and 2015. The majority 
(92%) of patients were referred from the Capital Re-
gion, seven patients (5.2%) were referred from the 
neighbouring Zealand Region, one patient from the Re-
gion of Southern Denmark and three patients were re-
ferred directly from their general practitioner. Informa-
tion regarding originating region was inaccessible in 15 
cases. Patients were primarily referred from out-patient 
clinics (74%), and the remaining patients were referred 
during a hospital admission. The referring sources in-
cluded a wide range of specialties, but patients were 
most often referred from a multidisciplinary wound 
care centre (67%) (Table 2).
Treatment duration
Half of the patients (53%) completed the prescribed 30 
sessions of HBOT. Of those, 19 (24%) patients were re-
ferred more than once for treatment of a DFU, meaning 
that the sessions were temporally separated by two or 
more HBOT courses. The actual number of patients 
who complied with the therapeutic treatment protocol 
was 59 patients (40%). 
Survival and amputation estimate
Overall, the median survival after first HBOT was 4.6 
years with a one- and five-year cumulated mortality of 
14.2% (95% confidence interval (CI): 9.5-21.0%) and 
51.8% (95% CI: 43.2-61.0%), respectively. The overall 
FIGURE 1
The distribution of Charlson Comorbidity Index with proportions of patientsa. 
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a) Mean = 5.2 (standard deviation: ± 2.2), median = 5 (interquartile range: 4-6).
TABLE 2
Patients, n
Referring specialty
MWCCa   84
Orthopaedic   19
Vascular surgery     7
Nephrology     5
Plastic surgery     6
Urology     1
Endocrinology     1
General practitioner     3
Unknown   22
Total 148
Region and hospital
Capital Region:
Rigshospitalet   20
Bispebjerg Hospital   75
Steno Diabetes Centre     9
Hospital of Northern Zealand   10
Others     8
Region Zealand     7
Region of Southern Denmark     1
General practitioner     3
Unknown        15
Total 148
MWCC = multidisciplinary wound care centre.
a) Provides orthopaedic and endocrinological expertise.
Referral by region and 
specialty: the number 
of patients referred 
from each referring 
source and of patients 
referred from each  
region.
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median time to first amputation (all levels) after refer-
ral to HBOT was 0.9 years with a five-year cumulative 
risk of amputation of 73.3% (95% CI: 64.4-71.7%)  
(Figure 2A and B). 
A sub-group analysis showed a median survival 
time after referral to HBOT of 5.6 years for patients 
who had not undergone amputating procedures at the 
first HBOT, and 4.2 years for patients who were re-
ferred with amputations. The one-year cumulated mor-
talities were the same, whereas the five-year cumulated 
mortality was 43.1% (95% CI: 32.2-55.9%) for patients 
who were not amputated at the first HBOT and 61.0% 
(95% CI: 48.5-73.8%) for previously amputated pa-
tients (Figure 2C). 
The median time to first amputation (minor or ma-
jor) after referral to HBOT was 0.5 years for previously 
amputated patients and 1.5 years for previously non-
amputated patients. The one- and five-year cumulated 
risk of amputation was 44.3% (95% CI: 33.9-56.4%) 
and 66.6% (95% CI: 54.7-78.3%) for patients who  
had not been amputated at the time of referral, and 
61.5% (95% CI: 50.2-72.9%) and 81.9% (95% CI: 
67.5-92.6%), respectively, for patients who had been 
amputated prior to their referral (Figure 2D).
DISCUSSION 
The principal findings of this study were that the popu-
lation of patients who are treated with HBOT for DFU 
has a high prevalence of comorbidity with an initial me-
dian CCI score of five, as well as a poor prognosis with 
FIGURE 2
Kaplan­Meier survival and amputation estimate in the population of diabetic foot­ulcer patients referred to hyperbaric oxygen therapy (HBOT) in years of observation. 
A. Kaplan­Meier estimate of overall survival: time to death after HBOT start. B. Kaplan­Meier estimate of overall amputation after referral to hyperbaric oxygen therapy: 
time to first amputation after HBOT start. C. Kaplan­Meier survival estimate after referral to hyperbaric oxygen therapy of previously amputated and non­amputated 
patients: time to death after HBOT start. D. Kaplan­Meier amputation estimate after referral to HBOT for previously amputated and non­amputated patients: time to 
first amputation after HBOT start. 
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five-year amputation and mortality estimates of 73.5% 
and 51.8% after referral to HBOT, respectively.
Strength and limitations
The strengths of this study were the relatively large 
number of study subjects as well as its nationwide de-
sign, because HBOT of DFUs primarily takes place at a 
single location in Denmark. Furthermore, the quality 
and completeness of the national Danish registries pro-
vided data on the exact date and level of amputation 
[17], complete mortality follow-up and an even collec-
tion of comorbidity data.  
The limitations of the study include
• Imprecise registration of diabetes subtype: 78 pa-
tients were registered with both diabetes Type 1 
and Type 2, which indicates that the DNPR cannot 
be used reliably to diagnose the subtype of diabe-
tes in DFU patients.
• Information bias regarding comorbidity and diabe-
tes complications. Study results are limited to CCI 
scores at the time of referral and Kaplan Meier es-
timates of survival and amputation. Comorbid con-
ditions might be missing.
• Selection bias; three patients were described as 
having diabetes in the electronic patient record 
without being registered with this diagnosis in the 
DNPR. However, the confirmation of the diabetes 
diagnosis in electronic patient records and the 
DNPR ensured a high probability of a correct diag-
nosis in all included patients. 
• The study design did not allow for evaluation of 
the relationship between grade of ulceration, per-
ipheral vascular disease, response to treatment 
and mortality. 
Previous literature in the field 
Our cohort had a high level of comorbidity (Figure 1).  
A non-HBOT study from the United Kingdom of new-
onset DFU patients with an equivalent age found a 
mean CCI of 1.2 (SD: ± 1.6) at the first DFU hospital  
visit and a one-year mortality rate of 8.1% and a five-
year mortality rate of 42.2% [3]. The survival rates in 
that study were comparable to ours, despite a remarka-
bly higher median CCI score in our cohort (mean = 5.2 
(SD: ± 2.2)). HBOT is a systemic treatment that im-
proves microcapillary tissue perfusion, and which may 
have a cardio-protective effect in diabetic patients with 
foot ulcers [18]. We speculate whether the equivalent 
mortality rate of previously amputated and non-ampu-
tated patients in the two first years after HBOT is indica-
tive of such an effect (see Figure 2C). The significant 
burden of disease was also evident from the high num-
ber of amputations in our study. Half of the referred pa-
tients (47%) had already received an amputation before 
they were referred to HBOT. To our knowledge, no pre-
vious studies have compared survival and amputation 
rates for patients referred to HBOT with and without 
previous amputations. Our data show that the prognosis 
is noticeably poorer if patients have been amputated be-
fore their referral to HBOT. The high burden of comor-
bidity entailed a low rate of treatment completion in the 
investigated cohort. A Swedish HBOT study including 
patients with DFU with less severe foot ulcers reported 
an adherence of 80%, whereas only 40% of our patients 
completed the prescribed 30 sessions of HBOT [11]. 
Possible mechanisms and implications
According to international guidelines, HBOT is re-
commended as adjuvant therapy in patients with full-
skin foot ulcers that have shown no significant impro-
vement after 30 days of standard wound care [14].  
An expected high number of Danish DFU patients meet 
these criteria for adjuvant HBOT. However, currently 
there is no standard practice for referral of patients 
with DFUs to HBOT in Denmark. The Danish Health 
Authority’s latest clinical guideline on DFU treatment 
[1] states that HBOT should; 1) not be routine, and  
2) be reserved for patients in whom all other treat-
ments have been attempted, and 3) should only be 
used in established scientific investigations. 
The significant burden of comorbidity in our study 
population is indicative of a practice of late referral to 
HBOT. In the absence of a Danish national clinical 
guideline for referral of DFUs to HBOT, a pattern has 
developed where only the fraction of the population 
with the most complicated DFUs and the highest bur-
den of disease is referred to this potentially advantage-
ous treatment. However, the administration of HBOT 
for such advanced disease stages is untimely if the debi-
litating consequences of DFUs should be prevented.  
In our cohort, 47% had already been amputated at the 
time of their referral with an average of four amputa-
tions per patient. Previous reports have revealed that 
HBOT reduces the risk of major amputation in patients 
with DFU if HBOT is initiated timely [19].
The HBO chamber located at Rigshospitalet has a 
regional service covering both the Capital Region and 
the Zealand Region for all elective HBOT procedures. 
In the present study, we found that persons with DFUs 
attending wound care treatment at two specific hos-
pitals in Copenhagen (71%) were far more likely to be 
offered HBOT than people with DFUs who lived in the 
Zealand Region, even though the prevalence of DFU is 
evenly distributed across the country [20]. This illus-
trate that in the absence of a national clinical guideline, 
the referral of DFU patients to adjunctive HBOT in 
Denmark is influenced by geography, attending phys-
ician or local procedures, causing unequal access to  
treatment of this debilitating disorder. 
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CONCLUSIONS
In the present study, the referral of patients with DFU 
to adjuvant HBOT in Denmark hinged on local factors 
rather than standardised procedures, and the patients 
were in advanced stages of their disease at the time of 
referral. The study results endorse the need for a large-
scale randomised controlled trial that can define a 
HBOT-sensitive target group of patients with DFU in 
order to instigate evidence-based use of HBOT and re-
duce the risk of HBOT overuse.
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